Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1326 ARTÍCULOS , VIENDO DEL 136 AL 150

Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis

Avants BB, Cook PA, Ungar L, Gee JC, Grossman M.

Neuroimage. 2010 Apr 15;50(3):1004-16. doi: 10.1016/j.neuroimage.2010.01.041. Epub 2010 Jan 18.

Sertraline for the treatment of depression in Alzheimer disease

Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2010 Feb;18(2):136-45. doi: 10.1097/JGP.0b013e3181c796eb.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

Discovery of notch-sparing gamma-secretase inhibitors

Augelli-Szafran CE, Wei HX, Lu D, Zhang J, Gu Y, Yang T, Osenkowski P, Ye W, Wolfe MS.

Curr Alzheimer Res. 2010 May;7(3):207-9. doi: 10.2174/156720510791050920.

New methods to explore marine resources for Alzheimer's therapeutics

Williams P, Sorribas A, Liang Z.

Curr Alzheimer Res. 2010 May;7(3):210-3. doi: 10.2174/156720510791050812.

Does religiosity protect against cognitive and behavioral decline in Alzheimer's dementia?

Coin A, Perissinotto E, Najjar M, Girardi A, Inelmen EM, Enzi G, Manzato E, Sergi G.

Curr Alzheimer Res. 2010 Aug;7(5):445-52. doi: 10.2174/156720510791383886.

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

Sadowsky CH, Farlow MR, Meng X, Olin JT.

Int J Clin Pract. 2010 Jan;64(2):188-93. doi: 10.1111/j.1742-1241.2009.02253.x.

APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis

Crews L, Rockenstein E, Masliah E.

Brain Struct Funct. 2010 Mar;214(2-3):111-26. doi: 10.1007/s00429-009-0232-6. Epub 2009 Nov 29.

Epigenetic regulation in the pathophysiology of Alzheimer's disease

Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HW, van den Hove DL.

Prog Neurobiol. 2010 Apr;90(4):498-510. doi: 10.1016/j.pneurobio.2010.01.002. Epub 2010 Jan 25.

Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer's disease

Wei LL, Shen YD, Zhang YC, Hu XY, Lu PL, Wang L, Chen W.

Neurosci Bull. 2010 Feb;26(1):77-84. doi: 10.1007/s12264-010-0703-z.

Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?

Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X.

Mol Neurobiol. 2010 Jun;41(2-3):87-96. doi: 10.1007/s12035-009-8095-7. Epub 2010 Jan 27.

Neuronal cholesterol esterification by ACAT1 in Alzheimer's disease

Chang TY, Chang CC, Bryleva E, Rogers MA, Murphy SR.

IUBMB Life. 2010 Apr;62(4):261-7. doi: 10.1002/iub.305.

Relationship between tau pathology and neuroinflammation in Alzheimer's disease

Metcalfe MJ, Figueiredo-Pereira ME.

Mt Sinai J Med. 2010 Jan-Feb;77(1):50-8. doi: 10.1002/msj.20163.

Current treatment and recent clinical research in Alzheimer's disease

Neugroschl J, Sano M.

Mt Sinai J Med. 2010 Jan-Feb;77(1):3-16. doi: 10.1002/msj.20165.

Vaccination as a therapeutic approach to Alzheimer's disease

Wisniewski T, Boutajangout A.

Mt Sinai J Med. 2010 Jan-Feb;77(1):17-31. doi: 10.1002/msj.20156.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias